Parallax Volatility Advisers, L.P. Alnylam Pharmaceuticals, Inc. Put Options Transaction History

Parallax Volatility Advisers, L.P.

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$233.81 - $287.01 $26.5 Million - $32.5 Million	113,300 New	113,300 $31.2 Million
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $861,821 - $1.19 Million	6,700 Added 36.61%	25,000 $4.24 Million
Q4 2020 Feb 16, 2021	SELL	$122.97 - $147.0 $4.51 Million - $5.39 Million	-36,700 Reduced 66.73%	18,300 $2.38 Million
Q3 2020 Nov 13, 2020	BUY	$121.19 - $165.49 $824,092 - $1.13 Million	6,800 Added 14.11%	55,000 $8.01 Million
Q2 2020 Aug 14, 2020	BUY	$104.21 - $156.44 $4.44 Million - $6.66 Million	42,600 Added 760.71%	48,200 $7.14 Million
Q1 2020 May 15, 2020	SELL	$93.12 - $133.99 $595,968 - $857,536	-6,400 Reduced 53.33%	5,600 $613,000
Q4 2019 Feb 14, 2020	BUY	$74.51 - $124.23 $149,020 - $248,460	2,000 Added 20.0%	12,000 $1.38 Million
Q3 2018 Nov 14, 2018	BUY	$87.52 - $122.67 $875,200 - $1.23 Million	10,000 New	10,000 $875,000
Q1 2018 May 15, 2018	SELL	$115.92 - $148.54 $1.16 Million - $1.49 Million	-10,000 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$114.49 - $139.98 $1.14 Million - $1.4 Million	10,000	10,000 $1.27 Million

643

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.